These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30467045)

  • 1. Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding.
    Dall'Olio FG; Sperandi F; Rihawi K; Gargiulo M; Melotti B; Brocchi S; Gelsomino F; Ardizzoni A
    J Thorac Oncol; 2018 Dec; 13(12):e247-e248. PubMed ID: 30467045
    [No Abstract]   [Full Text] [Related]  

  • 2. Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab.
    Keung YK; Hu EH
    J Oncol Pharm Pract; 2019 Jul; 25(5):1261-1264. PubMed ID: 29984627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
    Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
    Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
    [No Abstract]   [Full Text] [Related]  

  • 4. New onset of psoriasis during nivolumab treatment for lung cancer.
    Chujo S; Asahina A; Itoh Y; Kobayashi K; Sueki H; Ishiji T; Umezawa Y; Nakagawa H
    J Dermatol; 2018 Mar; 45(3):e55-e56. PubMed ID: 29205470
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
    Karakas Y; Yuce D; Kılıckap S
    Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report.
    Jiang R; Xu L; Huang Y; Fang C; Guo H; Li S; Wu J; Du Z
    Pancreas; 2018 Sep; 47(8):e53-e54. PubMed ID: 30113432
    [No Abstract]   [Full Text] [Related]  

  • 7. Arterial thrombosis and anti-PD-1 blockade.
    Boutros C; Scoazec JY; Mateus C; Routier E; Roy S; Robert C
    Eur J Cancer; 2018 Mar; 91():164-166. PubMed ID: 29289455
    [No Abstract]   [Full Text] [Related]  

  • 8. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
    Kwon CW; Land AS; Smoller BR; Scott G; Beck LA; Mercurio MG
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e349-e350. PubMed ID: 28129461
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
    Edahiro R; Shiroyama T; Hijiki S; Nojima S; Shirai Y; Koyama S; Kumanogoh A
    Lung Cancer; 2020 Feb; 140():116-117. PubMed ID: 31848027
    [No Abstract]   [Full Text] [Related]  

  • 10. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
    Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.
    Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T
    Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074
    [No Abstract]   [Full Text] [Related]  

  • 12. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
    Hida T
    Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.
    Lee SY; Kim MH; Jang M; Park Y; Cho BC
    Eur J Cancer; 2018 Nov; 104():104-107. PubMed ID: 30342309
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series.
    Tomelleri A; Campochiaro C; De Luca G; Cavalli G; Dagna L
    Eur J Intern Med; 2018 Nov; 57():e11-e12. PubMed ID: 30076088
    [No Abstract]   [Full Text] [Related]  

  • 15. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
    Salem JE; Allenbach Y; Vozy A; Brechot N; Johnson DB; Moslehi JJ; Kerneis M
    N Engl J Med; 2019 Jun; 380(24):2377-2379. PubMed ID: 31189043
    [No Abstract]   [Full Text] [Related]  

  • 16. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.
    Widick P; Gill RR; Mantia C; Costa DB; Rangachari D
    Clin Lung Cancer; 2020 Jan; 21(1):e6-e9. PubMed ID: 31640925
    [No Abstract]   [Full Text] [Related]  

  • 17. Nivolumab-induced Pancreatitis: An Immune-related Adverse Event.
    Saito H; Ono K
    Radiology; 2019 Dec; 293(3):521. PubMed ID: 31617817
    [No Abstract]   [Full Text] [Related]  

  • 18. Checkpoint Inhibitor-Induced Rejection of a Liver Allograft: A Combination of Acute T Cell-Mediated and Antibody-Mediated Rejection.
    Lee BT; Horwich BH; Chopra S; Ahearn A; Han HH
    Liver Transpl; 2019 Dec; 25(12):1845-1848. PubMed ID: 31408574
    [No Abstract]   [Full Text] [Related]  

  • 19. A Cautionary Note: "Real-World" Toxicity of Checkpoint Inhibitors.
    Markman M
    Oncology; 2018; 94(5):257-258. PubMed ID: 29444519
    [No Abstract]   [Full Text] [Related]  

  • 20. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
    Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
    Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.